OSE Immunotherapeutics Receives €200,000 from Nantes Metropole to Develop CoVepiT, its COVID-19 Prophylactic Vaccine Program
(WorldNews France)

OSE Immunotherapeutics Receives €200,000 from Nantes Metropole to Develop CoVepiT, its COVID-19 Prophylactic Vaccine Program 16 Jul 2020 07:30 CEST Company Name OSE IMMUNO ISN FR0012127173 Market Euronext Symbol OSE Regulatory News: OSE Immunotherapeutics (Paris:OSE) (ISIN: FR0012127173; Mn&eaigu;mo: OSE) today announced it will receive a grant of up to €200,000 from Nantes Metropole, the metropolitan area of Nantes community, dedicated to the development of a prophylactic vaccine against the pandemic virus SARS-CoV-2. This funding was awarded as part of the Metropolitan Fund to Support Health Innovations Linked to the COVID-19 Health Crisis, a €1 million fund created by Nantes Metropole for...